GHRS · GH Research PLC

The thesis

GH Research's shares have stayed above the $18.00 price of the company's April 2026 equity offering, and the pivotal-trial start in treatment-resistant depression (TRD) decides whether they hold there. The third-quarter 2026 update, projected for about 5 November 2026 by an earnings tracker and not yet confirmed by the company, is the next read on whether the late-2026 start target and an FDA-agreed design are intact.

The shares closed at $19.18 on 26 October 2026, according to split- and dividend-adjusted daily closes. That is 37.4% below the $30.64 52-week high and 31.5% lower over three months. The 14-day relative strength index (RSI), a momentum gauge where readings under 30 mark heavy selling, was 36.1, against 17.9 on 13 October 2026.

The takeover narrative is dead: Lilly completed its AtaiBeckley purchase on 11 September 2026, GH Research has disclosed no sale process, and the shares have traded below the roughly $26 deal-day level since 25 September 2026. The clinical story is unchanged from the company's 6 August 2026 second-quarter report. No company release or filing has appeared since that report, so the price decline carries no disclosed cause.

Bullish and bearish views on GH Research PLC

The bull case on GH Research PLC (GHRS), in brief: Phase 2b efficacy data are strong. The bear case: The takeover premium has gone.

Bull case

• Phase 2b efficacy data are strong. The company's 14 May 2026 first-quarter release cited 57.5% remission at Day 8 and 73% at six months in the GH001 Phase 2b TRD trial, published in JAMA Psychiatry. The primary endpoint showed a 15.5-point MADRS (depression rating scale) reduction versus placebo at Day 8 (p<0.0001).
• Regulatory obstacles have narrowed. The FDA lifted its clinical hold on GH001 in January 2026. The 6 August 2026 report said July FDA written feedback found the chemistry, manufacturing and controls and device plans Phase 3 ready.

• A large drugmaker paid for the mechanism. Lilly agreed on 16 July 2026 to buy AtaiBeckley, whose BPL-003 is also a 5-MeO-DMT (mebufotenin) depression drug, for up to $3.8 billion, and completed the deal on 11 September 2026.
• Patent life extends to 2043. The 6 August 2026 report noted a new U.S. patent covering aerosol mebufotenin treatment of major depressive disorder and TRD, expected to last to at least 2043.

Bear case

• The takeover premium has gone. The 26 October 2026 close of $19.18 is well under the roughly $26 level reached on the 16 July 2026 deal-day move. No second large-company deal for a psychedelic depression asset has been announced.
• The decline has no disclosed cause. The shares closed at $23.48 on 30 September 2026 and $18.85 on 13 October 2026, with no company release in between. A slight recovery to $19.18 has not changed that.
• The trial start has no date. The company guided only to initiation of the global pivotal program in 2026, and FDA design discussions were still continuing at 6 August 2026.
• Spending is rising. Second-quarter 2026 net loss was $15.1 million ($0.23 per share), against $9.3 million ($0.15 per share) a year earlier (6 August 2026 release), before any pivotal patient is enrolled.
• Analyst targets sit far above the price. On 30 August 2026, Stock Analysis recorded nine covering analysts, none rating the shares Hold or Sell, with targets of $38 to $65. The gap has widened since then.

Price setup

The adjusted daily closes show $19.18 on 26 October 2026, above the $18.00 April 2026 offering price. The shares closed at $18.85 on 13 October 2026, their low in the recent run of closes cited in the previous note. The 52-week high is $30.64.

The 14-day RSI has risen from 17.9 to 36.1 between 13 October 2026 and 26 October 2026, so selling pressure has eased from its extreme. It remains below the 50 midpoint, and the shares are 37.4% under the 52-week high.

Crowding evidence is limited. No insider sales or new share issuance are recorded in company filings since the April 2026 offering. The earnings date is the one near-term event. The narrative has moved from takeover-driven to waiting on the trial start: attention has faded since the 11 September 2026 Lilly closing.

Catalysts, next 30 days

• ~31 December 2026, est. End of the guided window for the pivotal start. This falls outside 30 days but the case turns on it. A start with an agreed design lowers risk; a miss pushes the program into 2027.

Elapsed catalysts

• ~5 November 2026, est. Third-quarter 2026 results and business update. The company has not confirmed the date. The report shows whether the late-2026 pivotal start holds, whether a trial design is agreed, and how much cash was spent against $362.7 million at 30 June 2026. (passed 1d ago)
• October 2026 — European College of Neuropsychopharmacology Congress. The company's 6 August 2026 report said further GH001 posters were accepted for this meeting. New data would add detail to the Phase 2b record. (passed 92d ago)

What would change the view

The case breaks if the third-quarter update drops the 2026 pivotal-start target, or again reports FDA design talks without endpoint, blinding approach or trial size. A new equity offering before trial initiation would also break it, as would a quarter-end cash balance well below $362.7 million with no enrolment under way. An FDA request for added cardiovascular safety work would weaken it too.

On price, a daily close below $18, the April 2026 offering price, would show the shares losing the level where new investors bought. Confidence improves if the report confirms an agreed design and a start date, or if a second large-company deal in psychedelic depression follows Lilly's.

What it trades with

GH Research trades on its own clinical milestones. The one external link is the Lilly–AtaiBeckley deal: the 16 July 2026 announcement lifted the shares, and the fade since 25 September 2026 shows how much of that move was deal premium. Other psychedelic-depression developers react to the same class news, such as FDA positions on dosing and monitoring. As a clinical-stage biotech, GH Research also moves with small-cap biotech funding conditions.